ARDS in Surgical Patients — Berlin Definition, Low-Tidal-Volume Ventilation, Prone Positioning, Conservative Fluids and ECMO Rescue

Day 2 after laparotomy, P/F 118 on PEEP 10, bilateral opacities, no murmur, no wheeze, fluids already 6 litres positive. Is this ARDS, overload, atelectasis or pneumonia — and what do you change on the ventilator in the next ten minutes? The examiner will watch you define it by Berlin, set the volumes by ARDSNet, prone by PROSEVA, dry by FACTT, and rescue by EOLIA. This page teaches all five moves with every number taken from the papers named beside it.^[1][2]

Overview & Definition — the Berlin consensus and what it replaced

Using a consensus process, a panel of experts convened in 2011 — an ESICM initiative endorsed by ATS and SCCM — and built the Berlin Definition on feasibility, reliability, validity and empirical testing.^[1] A draft definition proposed 3 mutually exclusive categories of ARDS based on degree of hypoxemia.^[1] The final bands every candidate recites are mild (P/F 200-300), moderate (100-200) and severe (100 or below) on PEEP, with acute onset, bilateral opacities and non-cardiac edema — and the four ancillary severe-ARDS variables trialled in the draft (radiographic severity, compliance, PEEP, minute volume) were dropped when they added no predictive validity.^[1]

Stages of mild, moderate, and severe ARDS were associated with increased mortality.^[1] The ladder is explicit: increased mortality (27%; 95% CI, 24%-30%; 32%; 95% CI, 29%-34%; and 45%; 95% CI, 42%-48%, respectively) with median ventilator days rising 5 to 7 to 9 in survivors.^[1] Compared with the AECC definition, the final Berlin Definition had better predictive validity for mortality.^[1]

Classification — three bands, one trajectory

^{[1] [2] [4] [11]}

Each band is a management escalation, not a label — the P/F sets the next intervention, and the trajectory across bands matters more than any single gas.^[1][20]

Epidemiology & Risk Factors — the LUNG SAFE denominators

Of 29,144 patients admitted to participating ICUs, 3022 (10.4%) fulfilled ARDS criteria.^[2] ARDS represented 0.42 cases per ICU bed over 4 weeks and represented 10.4% (95% CI, 10.0%-10.7%) of ICU admissions and 23.4% of patients requiring mechanical ventilation.^[2] This was a 459-ICU, 50-country winter snapshot — the best global denominator the viva owns.

Recognition is the scandal the examiner probes. Clinical recognition of ARDS ranged from 51.3% (95% CI, 47.5%-55.0%) in mild to 78.5% (95% CI, 74.8%-81.8%) in severe ARDS.^[2] Prone positioning was used in 16.3% (95% CI, 13.7%-19.2%) of patients with severe ARDS.^[2] Plateau pressure was measured in 40.1% (95% CI, 38.2-42.1), whereas 82.6% (95% CI, 81.0%-84.1%) received PEEP below 12 cm H2O (the abstract's own wording carries a spelling slip for expiratory).^[2] Under-recognition plus under-treatment is the LUNG SAFE moral — screen protocolised, measure plateau, prone the severe.

Hospital mortality was 34.9% (95% CI, 31.4%-38.5%) for those with mild, 40.3% (95% CI, 37.4%-43.3%) for those with moderate, and 46.1% (95% CI, 41.9%-50.4%) for those with severe ARDS.^[2] Surgical triggers feeding this pool: sepsis and pneumonia first, then aspiration, transfusion, major abdominal/thoracic surgery and trauma — with postoperative cases forming 42% of one large intubated cohort.^[20]

Pathophysiology — the baby lung, VILI, and the driving-pressure dial

Compliance tracks the aerated remainder — the baby lung — so a normal-sized breath delivered to a shrunken lung overdistends. Among ventilation variables, driving pressure was most strongly associated with survival.^[15] A 1-SD increment in driving pressure (approximately 7 cm of water) was associated with increased mortality (relative risk, 1.41; 95% CI, 1.31 to 1.51) — even in patients receiving protective plateau pressures and tidal volumes.^[15] Individual changes in VT or PEEP after randomization were not independently associated with survival; they were associated only if they were among the changes that led to reductions in driving pressure.^[15]

The trial-cohort confirmation is independent: when ventilating patients with low VT, driving pressure is a risk factor for death in ARDS patients, as is plateau pressure or compliance.^[16] PEEP and VT were not associated with death in any model.^[16] The bedside translation is one sentence: set volumes by predicted body weight, then minimise driving pressure (plateau minus PEEP) rather than chasing either dial alone.^[15][16]

VILI completes the triad: volutrauma from overdistension, atelectrauma from cyclic recruitment, biotrauma from inflammatory mediation — the mechanisms low volumes, adequate PEEP and proning each oppose.^[3][4]

Clinical Presentation — the postoperative deteriorator

The surgical ARDS story declares itself 24-72 hours after the insult: rising FiO2 to hold saturation, falling compliance, bilateral opacities on a portable film, and a P/F sliding through the Berlin bands while the abdomen stays the prime suspect.^[1][20] Postoperative ARDS showed more favorable early trajectories than medical ARDS — but lower 90-day mortality (36% vs 49%) still means one in three dies.^[20]

Entry phenotypes the examiner names: PROSEVA severe (P/F below 150 on FiO2 0.6+, PEEP 5+, near-6 mL/kg volumes).^[4] EOLIA very-severe rescue (P/F below 50 for 3+ hours, below 80 for 6+ hours, or acidemia with hypercapnia).^[5] CESAR severe-but-reversible (Murray above 3.0 or pH below 7.20, age 18-65).^[7]

^{[4] [3] [10] [5]}

Differential Diagnosis — leak versus pressure versus collapse versus infection

^{[1] [21] [20]}

Name the mimic set aloud before committing to ARDS — the viva rewards the candidate who excludes overload, collapse, cardiac failure and embolism with a test each.^[1][20]

Clinical & Bedside Assessment — bands, plateau, and the pressure that predicts

Band every gas by Berlin and attach the mortality: 27/32/45% across mild, moderate and severe disease.^[1] Measure plateau pressure as routine — LUNG SAFE shows it is measured in a minority (40.1%), which is itself a care failure.^[2] Then compute driving pressure (plateau minus PEEP): among ventilation variables it stratified risk best, and a 7 cm H2O rise carried a relative risk of 1.41 even under protective settings.^[15]

Investigations — gases for entry, imaging for the criterion, echo for the split

Track arterial gases against entry thresholds: PROSEVA below-150 for proning, EOLIA below-50/below-80 plus acidemia-hypercapnia for rescue referral.^[4][5] Demand bilateral opacities on imaging for the Berlin criterion — and use the same film to exclude lobar collapse, large effusion and pneumothorax before proning or cannulation.^[1] Split leak from cardiac failure with bedside echo and volume assessment: postoperative overload is the commonest false ARDS, and diuretic-responsive edema was never ARDS.^[1][20]

Hunt the trigger by context: cultures plus source imaging in sepsis; sputum and viral panels in pneumonia; transfusion timing; and in postoperative cases the surgical abdomen itself — leak, collection, ascites under pressure — because postoperative death tracks extrapulmonary organ dysfunction and surgical context, not lung numbers.^[20]

Management — Ventilation: 6 mL/kg, plateau limits, and the HFOV prohibition

The trial compared traditional ventilation treatment — 12 mL/kg predicted body weight with plateau capped at 50 cm H2O — against lower tidal volumes of 6 mL/kg with plateau capped at 30 cm H2O.^[3] The trial was stopped after the enrollment of 861 patients because mortality was lower in the group treated with lower tidal volumes than in the group treated with traditional tidal volumes (31.0 percent vs. 39.8 percent).^[3] Ventilator-free days favoured low volumes too: the number of days without ventilator use during the first 28 days after randomization was greater in this group (mean 12 vs 10 days).^[3] The conclusion is the viva sentence: in acute lung injury and ARDS, mechanical ventilation with a lower tidal volume than traditionally used results in decreased mortality and increases the number of days without ventilator use.^[3]

Set every ventilator from this platform: volumes by predicted (not actual) body weight, plateau ceiling 30 cm H2O, PEEP adequate but honest — PEEP and VT alone were not associated with death; only their effect through driving pressure was.^[15][16] And never offer HFOV: adults with new-onset moderate-severe ARDS were randomised to recruitment-targeted HFOV versus low-volume high-PEEP control, the trial was stopped after 548 of a planned 1200 randomisations, and in-hospital mortality was 47% with HFOV versus 35% control (relative risk 1.33) — with more blockade and more pressors in the HFOV arm.^[17]

Management — Definitive & Stepwise: prone, fluids, blockade, steroids, rescue

Prone early and long. 466 severe-ARDS patients were randomised to prone sessions of at least 16 hours or supine care.^[4] 28-day death was 16.0% prone versus 32.8% supine (hazard ratio 0.39); 90-day death 23.6% versus 41.0% (hazard ratio 0.44) — with no excess complications except more cardiac arrests in the supine group.^[4] Proning is the highest-yield move after low volumes; LUNG SAFE underuse (16.3% of severe ARDS) is the gap to name.^[2]

Fluids conservative once shock resolves. 1000 acute-lung-injury patients were managed by explicit 7-day conservative versus liberal protocols.^[12] Death at 60 days was 25.5% versus 28.4% (no significant difference) despite a 7-litre balance separation (−136 vs +6992 mL) — while the conservative strategy improved the oxygenation index and increased ventilator-free days (14.6 vs 12.1), without more shock or dialysis (10% vs 14%).^[12] The simplified Lite protocol matched this: mortality not different across arms (24% Lite, 25% conservative and liberal), with less new shock under Lite (9% vs 13%) and equal kidneys (58% vs 57%).^[13] In the 244 surgical patients specifically, death did not vary with fluids or catheter — but conservative fluids added ventilator-free days (15 vs 13) and ICU-free days without renal cost.^[14] The surgeon's rule: resuscitate shock generously, then dry the lung.^[12][14]

Blockade for dyssynchrony, never routine. ACURASYS gave 48 hours of cisatracurium versus placebo to 340 early severe-ARDS patients: adjusted 90-day hazard ratio 0.68, crude death 31.6% versus 40.7%, with no extra ICU paresis.^[9] ROSE then tested early continuous blockade against lighter-sedation usual care in 1006 patients at a median 7.6 hours — stopped at the second interim for futility with 90-day death 42.5% versus 42.8%, less activity and more cardiovascular events under blockade.^[10] Present both without forcing agreement: paralyze the fighting ventilator, not the merely hypoxemic patient.^[9][10]

Steroids: dexamethasone 20 mg to 10 mg. Patients received 20 mg IV daily on days 1-5, reduced to 10 mg daily on days 6-10, in established moderate-severe ARDS.^[11] At 60 days 21% versus 36% had died, with more ventilator-free days in the steroid arm.^[11] Harms were honest and balanced: hyperglycaemia 76% versus 70%, new ICU infections 24% versus 25%, barotrauma 10% versus 7% — no significant difference.^[11] Early dexamethasone could reduce ventilation duration and overall mortality in established moderate-severe ARDS — offer it, monitor glucose, do not promise infection-freedom.^[11]

Rescue: ECMO for the very severe. CESAR randomised 180 adults to ECMO consideration versus conventional care (75% actually received ECMO): disability-free survival at 6 months 63% versus 47% (relative risk 0.69).^[7] EOLIA randomised 249 very-severe patients: 60-day death 35% versus 46% (relative risk 0.76, CI 0.55-1.04) — not significant — with 28% of controls crossing to rescue ECMO (57% of crossovers died) and more transfusion-bleeding on ECMO (46% versus 28%).^[5] The Bayesian read gives 96% posterior probability of any mortality benefit and 92% of a 2%+ absolute reduction — but only 18% of reaching the originally hoped RR 0.67.^[6] The individual-patient-data verdict across both trials: 90-day treatment failure RR 0.65, mortality significantly lowered, more days alive out of ICU and free of organ failures — with rescue ECMO used in 17% of controls.^[8] Refer early to an ECMO centre; crossover means the control arm was never no-ECMO.^[5][8]

^{[1] [3] [4] [14] [20] [5]}

Specific Subtypes & Scenarios — postoperative ARDS and the two phenotypes

Postoperative ARDS is its own subtype. Among 1077 intubated ARDS patients, 455 (42%) had postoperative disease — with more favorable early trajectories and lower 90-day mortality (36% vs 49%), an advantage surviving adjustment.^[20] The determinant split is the teaching point: postoperative death tracked extrapulmonary organ dysfunction and surgical context (oesophageal and upper-abdominal patterns), with no respiratory marker independently predictive — while medical death tracked P/F and driving pressure.^[20] So manage postoperative ARDS by perioperative prevention and early identification of surgery-related complications, not by chasing lung numbers.^[20]

Subphenotypes stratify risk and response. In 1022 patients across ARMA and ALVEOLI, a two-class model fit best: phenotype 2 is hyperinflammatory — higher biomarkers, more vasopressors, lower bicarbonate, more sepsis — with higher death and fewer free days in both cohorts.^[18] High-versus-low PEEP effects on death and free days differed by phenotype.^[18] Fluid strategy effects flipped too: liberal versus conservative 90-day death 26% versus 18% in type 1 but 40% versus 50% in type 2 — classifiable bedside by IL-8, bicarbonate and TNFR-1.^[19] Precision ventilation is coming; for now, name the heterogeneity when the patient defies the average.^[18][19]

Prevention at induction and emergence. Sugammadex versus neostigmine reversal in 3498 major abdominal/thoracic cases cut pulmonary-complication-or-death modestly — but the driver was atelectasis of uncertain significance, and ARDS was not reported.^[21] Quote SNaPP for atelectasis prevention, never as an ARDS trial.^[21]

Complications & Pitfalls — the errors examiners reward you for naming

The volume trap — 12 mL/kg kills 8-9 extra per hundred versus 6 mL/kg. Predicted weight, plateau 30, every patient.^[3]

The supine trap — severe ARDS left supine overnight without a prone plan repeats the LUNG SAFE failure (16.3% proned). 16 hours, early, P/F below 150.^[4][2]

The fluid trap — 7 litres positive with worsening P/F is FACTT-liberal physiology. Dry once perfused; the surgical lung earned extra ventilator-free days dry.^[12][14]

The blockade trap — routine early paralysis after ROSE: no mortality gain, less mobility, more cardiovascular events. Dyssynchrony-only.^[10]

The HFOV trap — stopped early for 47% versus 35% harm. HFOV is not a rescue ladder rung.^[17]

The PEEP-number trap — quoting ALVEOLI/LOVS/EXPRESS primary numbers from memory. They sit outside this verified set; argue PEEP through driving pressure and phenotype response instead.^[15][18]

The SNaPP-overreach trap — claiming an ARDS rate from a trial that reported none. Atelectasis signal only.^[21]

Prognosis & Disposition — the ladder and where the patient goes

^{[1] [2] [3] [4] [12] [20]}

Every ARDS patient needs ICU-level care with lung-protective protocols and a rescue pathway — ward care after intubation criteria is a failure-to-rescue setup. Modifiers: severity band, driving pressure, extrapulmonary failures, surgical source control, age and frailty. Discharge with explicit re-escalation triggers: saturation, work of breathing, P/F trajectory, perfusion.^[1][15][20]

Special Populations — surgical contexts that change the emphasis

• Post-laparotomy: conservative fluids after resuscitation, leak/collection hunt first — death tracks the abdomen, not the P/F.^[14][20]
• Oesophagectomy and upper-abdominal surgery: highest postoperative-ARDS context; prevention (aspiration precautions, lung-protective intraoperative ventilation, reversal choice) outweighs rescue.^[20][21]
• Trauma with bleeding: blood-first resuscitation per the shock sibling, then FACTT-dry once perfused — the lung drowns in the resuscitation that saved the circulation.^[12]
• Elderly and frail: lower reserve, earlier ICU escalation, driving-pressure vigilance with small absolute volumes.^[15][2]
• Pregnancy: no verified obstetric-ARDS numbers sit in this pack — manage positioning, ventilation and delivery priorities by principle and name the evidence gap rather than inventing numbers.

Evidence, Guidelines & Regional Differences — the four stories and who led them

• The definition story (global): AECC 1994 → Berlin 2012 consensus-plus-empirics → better mortality prediction, severity bands with the 27/32/45 ladder.^[1]
• The ventilation story (US/Europe): ARDSNet 6 mL/kg platform → PROSEVA prone halving death → OSCILLATE HFOV harm → Amato/Guérin driving-pressure mediation → LUNG SAFE practice gap.^{[3][4][17][15][16][2]}
• The fluids-and-adjuncts story (US/France/Spain): FACTT conservative (Lite equivalence, surgical subgroup) → ACURASYS promise then ROSE futility for blockade → DEXA-ARDS steroids → subphenotype-by-fluid interaction.^{[12][13][14][9][10][11][19]}
• The rescue story (UK/France/global IPD): CESAR referral benefit → EOLIA near-miss with crossover → Bayesian 96% any-benefit read → IPD mortality verdict.^[7][5][6][8]
• The surgical story: postoperative ARDS as a distinct, extrapulmonary-driven subtype (prevention + complication-hunting) with SNaPP reversal as atelectasis prevention only.^[20][21]
• Sibling-topic boundary: shock owns pressors, perfusion targets and transfusion; postoperative sepsis owns fever timing, hour-1 antibiotics and leak hunting — this topic owns the lung. Cite each where it lives.

Exam Pearls — the one-liners that score

• Berlin in one breath: 2011 consensus, three hypoxemia bands, 27/32/45% death, beats AECC (0.577 vs 0.536).^[1]
• LUNG SAFE in one breath: 10.4% of ICU admissions, half of mild missed, 16.3% of severe proned, 34.9/40.3/46.1% death.^[2]
• Ventilation: 6 vs 12 mL/kg — 31.0% vs 39.8% death, +2 ventilator-free days; plateau 30 vs 50.^[3]
• Driving pressure: best risk variable — 7 cm H2O rise, RR 1.41; VT/PEEP matter only through it.^[15]
• Prone: 466 patients, 16+ hours — 16.0% vs 32.8% at 28 days (HR 0.39), 23.6% vs 41.0% at 90 days.^[4]
• Fluids: FACTT 25.5% vs 28.4% (ns) with +2.5 free days, no renal cost — surgical subgroup same story.^[12][14]
• Blockade: ACURASYS HR 0.68 vs ROSE futility at 42.5% vs 42.8% — dyssynchrony-only.^[9][10]
• Steroids: dexamethasone 20 mg x5 then 10 mg x5 — 21% vs 36% at 60 days.^[11]
• ECMO: CESAR 63% vs 47% → EOLIA 35% vs 46% (ns, crossover) → Bayesian 96% → IPD verdict significant.^[7][5][6][8]
• Postop distinctness: 42% of ARDS, 36% vs 49% death — hunt the abdomen, not the P/F.^[20]

Revision summary

Define by Berlin — three hypoxemia bands with the 27/32/45 mortality ladder and better-than-AECC prediction — set against LUNG SAFE reality (10.4% of ICU admissions, half missed, sixth proned, 34.9/40.3/46.1 dead).^[1][2] Ventilate 6 mL/kg to plateau 30 (31.0% vs 39.8% death), minimise driving pressure (RR 1.41 per 7 cm H2O; VT/PEEP count only through it), never HFOV (47% vs 35% harm).^{[3][15][16][17]} Prone severe disease 16+ hours (16.0% vs 32.8%, HR 0.39), dry the lung once shock resolves (FACTT +2.5 free days, surgical subgroup same, Lite equivalent), paralyze dyssynchrony only (ACURASYS vs ROSE futility), give dexamethasone 20-to-10 mg in established disease (21% vs 36%), and rescue very-severe refractory hypoxemia via ECMO pathways (CESAR → EOLIA → Bayesian 96% → IPD significant).^{[4][12][14][13][9][10][11][7][5][6][8]} Remember postoperative ARDS as its own extrapulmonary-driven subtype (42% of cases, 36% vs 49%) — prevention and complication-hunting first — with hyperinflammatory subphenotypes flipping fluid and PEEP responses.^[20][18][19]

The trial stopped at 88% enrolment with 60-day death 21% versus 36% and more ventilator-free days.^[6]

References21ShowHide

1. [1]Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA, 2012.PMID 22797452
2. [2]Bellani G, Laffey JG, Pham T, et al. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA, 2016.PMID 26903337
3. [3]Brower RG, Matthay MA, Morris A, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med, 2000.PMID 10793162
4. [4]Guérin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med, 2013.PMID 23688302
5. [5]Combes A, Hajage D, Capellier G, et al. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome. N Engl J Med, 2018.PMID 29791822
6. [6]Goligher EC, Tomlinson G, Hajage D, et al. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome and Posterior Probability of Mortality Benefit in a Post Hoc Bayesian Analysis of a Randomized Clinical Trial. JAMA, 2018.PMID 30347031
7. [7]Peek GJ, Mugford M, Tiruvoipati R, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet, 2009.PMID 19762075
8. [8]Combes A, Peek GJ, Hajage D, et al. ECMO for severe ARDS: systematic review and individual patient data meta-analysis. Intensive Care Med, 2020.PMID 33021684
9. [9]Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med, 2010.PMID 20843245
10. [10]Moss M, Huang DT, Brower RG, et al. Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome. N Engl J Med, 2019.PMID 31112383
11. [11]Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med, 2020.PMID 32043986
12. [12]Wiedemann HP, Wheeler AP, Bernard GR, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med, 2006.PMID 16714767
13. [13]Grissom CK, Hirshberg EL, Dickerson JB, et al. Fluid management with a simplified conservative protocol for the acute respiratory distress syndrome*. Crit Care Med, 2015.PMID 25599463
14. [14]Stewart RM, Park PK, Hunt JP, et al. Less is more: improved outcomes in surgical patients with conservative fluid administration and central venous catheter monitoring. J Am Coll Surg, 2009.PMID 19476825
15. [15]Amato MB, Meade MO, Slutsky AS, et al. Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med, 2015.PMID 25693014
16. [16]Guérin C, Papazian L, Reignier J, et al. Effect of driving pressure on mortality in ARDS patients during lung protective mechanical ventilation in two randomized controlled trials. Crit Care, 2016.PMID 27894328
17. [17]Ferguson ND, Cook DJ, Guyatt GH, et al. High-frequency oscillation in early acute respiratory distress syndrome. N Engl J Med, 2013.PMID 23339639
18. [18]Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med, 2014.PMID 24853585
19. [19]Famous KR, Delucchi K, Ware LB, et al. Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy. Am J Respir Crit Care Med, 2017.PMID 27513822
20. [20]Pensier J, Henry J, Aarab Y, et al. Is postoperative ARDS different from medical ARDS? Crit Care, 2026.PMID 42243987
21. [21]Leslie K, Darvall JN, Chan MTV, et al. Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (SNaPP): an international, randomised, controlled, phase 4 trial. Lancet Respir Med, 2026.PMID 42263720